LONDON: British pharmaceutical giant GlaxoSmithKline said Wednesday that 2023 net profits slumped, after a vast gain from the spin-off of its consumer healthcare unit Haleon skewed results of the previous year.
GSK Pakistan recognised as ‘top employer’
Profit after tax tumbled to £4.9 billion last year from £14.9 billion in 2022, GSK said in a results statement, adding however that operating profit excluding exceptional items rose.
Comments
Comments are closed.